COVID-19 Vaccine Hesitancy Among Rheumatic Diseases Patients

Overview

Rheumatological diseases (RD) are an important group of different clinical entities and specific diseases that affect a significant proportion of the world population. In Mexico, the RD have a relevant representation in the adult population. COVID-19 vaccination has been proposed as a measure to contain the COVID-19 pandemic. The vaccines have been shown to be effective and reasonably safe in the population without significant risk factors, which has allowed their approval to attend the health emergency. At present, there is little scientific information that allows a solid recommendation on vaccination for COVID-19 in patients with RD, although most authorities have spoken in favor of vaccination in immunocompromised patients, as are a relevant number of patients with RD. However, it is desirable to achieve herd immunity to facilitate the impact of vaccination on the transmission of SARS-CoV-2 infection. For this, it is required that around 70% -80% of the target population be vaccinated, which implies not only access to the vaccine but also accepting to be vaccinated. Vaccine hesitancy is defined as the delay or refusal to accept the vaccine when it is available by health services. Sometimes, they conceptualize it as a continuum and also includes the high demand from the population for the vaccine; In this continuum, there are variations in acceptance and rejection and multiple possible combinations, from acceptance with great concern about the decision to rejection of certain vaccines but not others. It is a complex, contextual, changing phenomenon, specific for each vaccine and the referred disease and probably influenced by cultural determinants.

Full Title of Study: “COVID-19 Vaccine Hesitancy Among Mexican Rheumatic Diseases Patients”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: August 30, 2021

Detailed Description

The objectives are: 1. – To measure the phenomenon of vaccine hesitancy in Mexican patients with RD from two Health Institutions in Mexico City. 2. – Translate and adapt the "Oxford Covid-19 vaccine hesitancy scale" to patients with RD and validate this version in a population of patients with RD from two Health Institutions in Mexico City 3. Explore factors associated with the phenomenon of vaccine hesitancy.

Interventions

  • Other: COVID-19 vaccine hesitancy scale in rheumatic diseases
    • The instrument was developed by Freeman et al, prior to its application, translation, cultural adaptation, and validation were performed.
  • Other: COVID-19 vaccine hesitancy associated factors
    • The instrument includes questions about the doctor-patient relationship, perception of the COVID-19 vaccine, perception of risk of COVID-19 infection, perception of the severity of the pandemic in Mexico, perception of the severity of their rheumatic disease, perception of the control of comorbidities, perception of the intensity of the immunosuppressive treatment, positioning of the patient towards vaccines for COVID-19

Arms, Groups and Cohorts

  • Rheumatic diseases outpatients
    • All the rheumatic diseases outpatients from the National Institute of Medical Sciences and General Hospital.

Clinical Trial Outcome Measures

Primary Measures

  • Measure the phenomenon of vaccine hesitancy among rheumatic diseases patients
    • Time Frame: At study inclusion
    • Identify the percentage of patients with rheumatic diseases that present COVID-19 vaccine hesitancy using the instrument developed by Freeman et al (translation, cultural adaptation, and validation performed)

Secondary Measures

  • Identify factors associated with COVID-19 vaccine hesitancy among rheumatic diseases patients
    • Time Frame: At study inclusion
    • Identify factors associated with COVID-19 vaccine hesitancy among rheumatic diseases patients using an instrument locally development

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with a rheumatic disease diagnosis according to their primary rheumatologist who agree to participate Exclusion Criteria:

  • Patients with a not confirmed rheumatic disease

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 99 Years

Investigator Details

  • Lead Sponsor
    • National Institute of Medical Sciences and Nutrition, Salvador Zubiran
  • Provider of Information About this Clinical Study
    • Principal Investigator: Virginia Pascual Ramos, PI – National Institute of Medical Sciences and Nutrition, Salvador Zubiran

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.